ArticleWorld journal of stem cells2012
Stem cell therapy independent of stemness.
Article in World journal of stem cells, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Regeneration process of severed rabbit common calcanean tendons influenced by external compression.Journal of orthopaedic surgery and research · 2024Article
- Therapeutic strategies to recover ependymal barrier after inflammatory damage: relevance for recovering neurogenesis during development.Frontiers in neuroscience · 2023Review
- Safety and therapeutic potential of human bone marrow-derived mesenchymal stromal cells in regenerative medicine.Stem cell investigation · 2021Review
- Mesenchymal stem cells as a multimodal treatment for nervous system diseases.Stem cells translational medicine · 2020Review
- Liver regeneration and alcoholic liver disease.Annals of translational medicine · 2020Review
- Neural Induction Potential and MRI of ADSCs Labeled Cationic Superparamagnetic Iron Oxide Nanoparticle In Vitro.Contrast media & molecular imaging · 2018Article
- Repair of Torn Avascular Meniscal Cartilage Using Undifferentiated Autologous Mesenchymal Stem Cells: From In Vitro Optimization to a First-in-Human Study.Stem cells translational medicine · 2017Article
- Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease.World journal of gastroenterology · 2016Review
- The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies.Advanced biomedical research · 2016Review
- Secreted factors from dental pulp stem cells improve glucose intolerance in streptozotocin-induced diabetic mice by increasing pancreatic β-cell function.BMJ open diabetes research & care · 2015Article
- Transforming growth factor Beta family: insight into the role of growth factors in regulation of fracture healing biology and potential clinical applications.Mediators of inflammation · 2015Review
- Enhancing the efficacy of mesenchymal stem cell therapy.World journal of stem cells · 2014Review
- Secreted Frizzled-related protein 2 as a target in antifibrotic therapeutic intervention.American journal of physiology. Cell physiology · 2014Article
- Assessment of stem cell carriers for tendon tissue engineering in pre-clinical models.Stem cell research & therapy · 2014Review
- Stem cells supporting other stem cells.Frontiers in genetics · 2013Review
- Age of the donor reduces the ability of human adipose-derived stem cells to alleviate symptoms in the experimental autoimmune encephalomyelitis mouse model.Stem cells translational medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cell (MSC) therapy is entering a new era shifting the focus from initial feasibility study to optimization of therapeutic efficacy. However, how MSC therapy facilitates tissue regeneration remains incompletely characterized. Consistent with the emerging notion that secretion of multiple growth factors/cytokines (trophic factors) by MSC provides the underlying tissue regenerative mechanism, the recent study by Bai et al demonstrated a critical therapeutic role of MSC-derived hepatocyte growth factor (HGF) in two animal models of multiple sclerosis (MS), which is a progressive autoimmune disorder caused by damage to the myelin sheath and loss of oligodendrocytes. Although current MS therapies are directed toward attenuation of the immune response, robust repair of myelin sheath likely requires a regenerative approach focusing on long-term replacement of the lost oligodendrocytes. This approach appears feasible because adult organs contain various populations of multipotent resident stem/progenitor cells that may be activated by MSC trophic factors as demonstrated by Bai et al This commentary highlights and discusses the major findings of their studies, emphasizing the anti-inflammatory function and trophic cross-talk mechanisms mediated by HGF and other MSC-derived trophic factors in sustaining the treatment benefits. Identification of multiple functionally synergistic trophic factors, such as HGF and vascular endothelial growth factor, can eventually lead to the development of efficacious cell-free therapeutic regimens targeting a broad spectrum of degenerative conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.